Currently, clinical trials of the HSF1 inhibitors quercetin and triptolide are being conducted for squamous cell carcinoma, gastric cancer, and breast cancer, although it remains unknown whether these drugs are specific inhibitors of HSF1 [146]. The gene discussed is HSF1; the disease is breast cancer.